Under the terms of the share purchase agreement, Antonius Stegmann, co-founder and chief scientific officer (CSO) of Virosome Biologicals, will remain CSO of Virosome Biologicals. The acquisition of
According to SyntheMed, Repel-CV is a bioresorbable film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce
Martek Biosciences, a developer of health and wellness products, has reported a net income of $9.6m, or $0.29 per diluted share, for the first quarter of fiscal 2009,
As a result of this sale, Sunesis and SARcode have terminated an earlier licensing agreement relating to this program, and Sunesis will forego future potential milestone payments and
The company raised approximately $15 million through equity contributions by existing investors, including ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Company, Unilever Technology
According to Teikoku, the transdermal formulation is a once-a-week patch that continuously delivers donepezil through the skin into the bloodstream. It will enable the number of doses to
Mindray Medical International, a developer, manufacturer and marketer of medical devices, has reported that GAAP net income was $31.6m, or $0.28 per diluted share, for the fourth quarter
MedX Health, a developer of drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, has received the CE Mark approval to market
pSivida, a drug delivery company, has completed enrollment of the BrachySil dose ranging clinical trial. The dose ranging study, conducted in the UK at Guy’s and St Thomas’
Quarter 4 2008 Results Revenues for quarter 4, 2008 amounted to $34.0 million compared to $35.7m for quarter 4, 2007, a decrease of 4.8%. This included a decrease
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.